Previous 10 | Next 10 |
Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Second Cohort Underway with Data Exp...
Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , May 6, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...
Gainers: Precipio (PRPO) +102%.Regional Health Properties (RHE) +94%.American Shared Hospital Services (AMS) +33%.Brooklyn ImmunoTherapeutics (BTX) +26%.Scully Royalty (SRL) +25%.Ocugen (OCGN) +23%.Top Ships (TOPS) +23%.Rezolute (RZLT) +20%.Milestone Scientific (MLSS) +19%.Ashford H...
Regulus Therapeutics (RGLS) announces top-line results from the first cohort of patients with ADPKD in its ongoing Phase 1b trial of RGLS4326.In the first cohort, nine patients were enrolled and received 1 mg/kg of RGLS4326 subcutaneously every other week for four doses. Safety, pharmacokinet...
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers Statistically ...
Regulus Therapeutics (RGLS) announces that it completed dosing in the first cohort of nine patients with Autosomal Dominant Polycystic Kidney Disease ((ADPKD)) in its Phase 1b clinical trial of RGLS4326.ADPKD, caused by the mutations in the PKD1 or PKD2 genes, is among the most common hu...
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire LA JOLLA, Calif. , April 15, 2021 /PRNewswire/ -- ...
Gainers: Cinedigm (CIDM) +20%.Grupo Televisa (TV) +20%.GameStop (GME) +18%.Nurix Therapeutics (NRIX) +18%.Centennial Resource Development (CDEV) +17%.Regulus Therapeutics (RGLS) +16%.NexImmune (NEXI) +16%.UP Fintech (TIGR) +16%.Kymera Therapeutics (KYMR) +15%.Transocean (RIG) +...
The Hottest Penny Stocks to Buy Could Be the Same Price As a Cup of Coffee Are penny stocks under $2 worth it? This is a question that many investors ask themselves regularly. Because the term penny stock means any stock trading under $5, there are thousands to choose from. Even if we n...
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire LA JOLLA, Calif. , April 7, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...